Panmure Gordon reaffirmed their buy rating on shares of Faron Pharmaceuticals Oy (LON:FARN) in a research note released on Monday, May 15th, StockTargetPrices.com reports. They currently have a GBX 663 ($8.39) price objective on the stock.
Shares of Faron Pharmaceuticals Oy (LON FARN) remained flat at GBX 735.00 during midday trading on Monday. The company had a trading volume of 332 shares. The stock’s market capitalization is GBX 193.39 million. The firm’s 50 day moving average is GBX 755.39 and its 200 day moving average is GBX 479.81. Faron Pharmaceuticals Oy has a 52-week low of GBX 240.75 and a 52-week high of GBX 825.00.
ILLEGAL ACTIVITY WARNING: “Faron Pharmaceuticals Oy’s (FARN) Buy Rating Reiterated at Panmure Gordon” was first posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://transcriptdaily.com/2017/06/17/faron-pharmaceuticals-oy-farn-earns-buy-rating-from-panmure-gordon-updated-updated-updated.html.
In other news, insider Jonathan Knowles acquired 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 25th. The stock was purchased at an average price of GBX 635 ($8.03) per share, for a total transaction of £6,350 ($8,032.89).
Faron Pharmaceuticals Oy Company Profile
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.